siRNAs targeted to Smad4 prevent renal fibrosis in vivo
Yoshiyuki Morishita1, Hiromichi Yoshizawa1, Minami Watanabe2
11] Division of Nephrology, Department of Medicine, Jichi Medical University, Tochigi, Japan [2].
Abstract:
Renal fibrosis is the final common pathway leading to decreased renal function. No therapy has been established to prevent it. In order to establish a therapeutic approach and target molecule for renal fibrosis, we investigated the effects of Smad4 knockdown by siRNAs on renal fibrosis in vivo. Renal fibrosis mice were produced by single intraperitoneal injection of folic acid. siRNAs targeted to Smad4 (Smad4-siRNAs) (5 nmol) were injected into each mouse by systemic tail vein injection three times per week. Non-targeted siRNAs (control-siRNAs) were injected in the same way for a control group. The siRNAs were delivered to the interstitial fibrous area and tubules. Smad4-siRNAs significantly knocked down Smad4 expression and inhibited renal fibrosis. They also inhibited α-SMA-positive myofibroblasts. Control-siRNAs did not show these effects. The results of this study suggest that Smad4 knockdown is one of the crucial therapeutic options for the prevention of renal fibrosis in vivo.
Insights
Smad4 knockdown using small interfering RNAs (siRNAs) effectively inhibited renal fibrosis in mice. This targeted approach reduced myofibroblast activation, suggesting a potential therapeutic strategy for preventing kidney fibrosis.
Area of Science:
- Nephrology
- Molecular Biology
- Biomedical Research
Background:
- Renal fibrosis is a major cause of kidney disease progression and loss of renal function.
- Currently, no established therapies exist to prevent or reverse renal fibrosis.
- Identifying novel therapeutic targets is crucial for managing kidney diseases.
Purpose of the Study:
- To investigate the therapeutic potential of Smad4 knockdown in preventing renal fibrosis in a mouse model.
- To determine if Smad4 is a viable molecular target for anti-fibrotic therapies.
Main Methods:
- Renal fibrosis was induced in mice via folic acid injection.
- Systemic administration of small interfering RNAs (siRNAs) targeting Smad4 (Smad4-siRNAs) or control siRNAs.
- Evaluation of Smad4 expression, renal fibrosis markers, and α-SMA-positive myofibroblasts.
Main Results:
- Smad4-siRNAs significantly reduced Smad4 expression in the kidneys.
- Smad4 knockdown effectively inhibited the progression of renal fibrosis.
- The treatment also suppressed the accumulation of α-SMA-positive myofibroblasts.
Conclusions:
- Smad4 knockdown demonstrates significant therapeutic potential for preventing renal fibrosis in vivo.
- Targeting Smad4 represents a promising strategy for developing new treatments for kidney fibrosis.
